November
2019
Preliminary Terms No. 2,818
Registration Statement Nos. 333-221595;
333-221595-01
Dated November 5, 2019
Filed pursuant to Rule 433
Morgan
Stanley Finance LLC
Structured
Investments
Opportunities in U.S. Equities
Contingent Income Auto-Callable Securities due
November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the
Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common
Stock of Kohl’s Corporation
Fully
and Unconditionally Guaranteed by Morgan Stanley
Principal at Risk Securities
The securities
offered are unsecured obligations of Morgan Stanley Finance LLC (“MSFL”) and are fully and unconditionally guaranteed
by Morgan Stanley. The securities have the terms described in the accompanying
product supplement and prospectus, as supplemented or modified by this document. The securities do not guarantee the repayment
of principal and do not provide for the regular payment of interest. Instead, the securities will pay a contingent monthly coupon
but only if the determination closing price of each of the common stock of Sarepta Therapeutics, Inc., the
common stock of Western Digital Corporation and the common stock of Kohl’s Corporation, which we refer to collectively as
the underlying stocks, is at or above 55% of its respective
initial share price, which we refer to as the respective coupon threshold level, on
the related observation date. If the determination closing price of any underlying stock is less than its respective downside
coupon level on any observation date, we will pay no interest for the related monthly period. However, if the determination closing
price of each of the underlying stocks is at or above its respective coupon threshold level on any subsequent observation date,
investors will receive, in addition to the contingent monthly coupon for the related monthly period, any previously unpaid contingent
monthly coupons from prior observation dates. In addition, the securities will be automatically redeemed if the determination closing
price of each underlying stock is greater than or equal to its respective redemption threshold level on
any monthly redemption determination date (beginning approximately three months after the original issue date) for
the early redemption payment equal to the sum of the stated principal amount plus the related contingent monthly coupon and any
previously unpaid contingent monthly coupons from prior observation dates. At maturity, if the securities have not previously
been redeemed and the final share price of each underlying stock is greater than or equal to 50% of its respective
initial share price, which we refer to as the respective downside threshold level, the payment at maturity will be the stated principal
amount and, if the final share price of each underlying stock is also greater than or equal to its respective coupon threshold
level, the related contingent monthly coupon and any previously unpaid contingent monthly coupons from prior observation dates.
However, if the final share price of any underlying stock is less than its respective downside threshold level, investors
will be exposed to the decline in the worst performing underlying stock on a 1-to-1 basis and will receive a payment at maturity
that is less than 50% of the stated principal amount of the securities and could be zero. Accordingly, investors in the
securities must be willing to accept the risk of losing their entire initial investment and also the risk of not receiving any
contingent monthly coupons throughout the 5-year term of the securities. These long-dated securities are for investors who
are willing to risk their principal and seek an opportunity to earn interest at a potentially above-market rate in exchange for
the risk of receiving no monthly interest over the entire 5-year term and in exchange for the possibility of an automatic early
redemption prior to maturity. Because the payment of contingent monthly coupons is based on the worst performing of the underlying
stocks, the fact that the securities are linked to three underlying stocks does not provide any asset diversification benefits
and instead means that a decline of any underlying stock below the relevant coupon threshold level will result in no contingent
monthly coupons, even if one or both of the other underlying stocks close at or above the respective coupon threshold levels. Because
all payments on the securities are based on the worst performing of the underlying stocks, a decline beyond the respective coupon
threshold level or respective downside threshold level, as applicable, of any underlying stock will result in no contingent monthly
coupon payments or a significant loss of your investment, as applicable, even if one or both of the other underlying stocks have
appreciated or have not declined as much. Investors will not participate in any appreciation of any underlying stock. The securities
are notes issued as part of MSFL’s Series A Global Medium-Term Notes program.
All payments are subject to our credit risk. If we default
on our obligations, you could lose some or all of your investment. These securities are not secured obligations and you will not
have any security interest in, or otherwise have any access to, any underlying reference asset or assets.
Issuer:
|
Morgan Stanley Finance LLC
|
Guarantor:
|
Morgan Stanley
|
Underlying stocks:
|
Sarepta Therapeutics, Inc. common stock (the “SRPT Stock”), Western Digital Corporation common stock (the “WDC Stock”) and Kohl’s Corporation common stock (the “KSS Stock”)
|
Aggregate principal amount:
|
$
|
Stated principal amount:
|
$1,000 per security
|
Issue price:
|
$1,000 per security
|
Pricing date:
|
November 21, 2019
|
Original issue date:
|
November 26, 2019 (3 business days after the pricing date)
|
Maturity date:
|
November 26, 2024
|
Early redemption:
|
The securities are not subject to early redemption until three
months after the original issue date. Following this three-month non-call period, if, on any redemption determination
date, beginning on February 21, 2020, the determination closing price of each underlying stock is greater than or equal
to its respective redemption threshold level, the securities will be automatically redeemed for an early redemption payment on
the related early redemption date. No further payments will be made on the securities once they have been redeemed.
The securities will not be redeemed early on any early redemption
date if the determination closing price of any underlying stock is below its respective redemption threshold level on the related
redemption determination date.
|
Early redemption payment:
|
The early redemption payment will be an amount equal to (i) the stated principal amount for each security you hold plus (ii) the contingent monthly coupon with respect to the related observation date and any previously unpaid contingent monthly coupons from the prior observation dates.
|
Determination closing price:
|
With respect to each underlying stock, the closing price of such underlying stock on any redemption determination date or observation date (other than the final observation date), times the adjustment factor on such determination date or observation date, as applicable
|
Early redemption dates:
|
Beginning on February 26, 2020, monthly. See “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below. If any such day is not a business day, that early redemption payment, if payable, will be made on the next succeeding business day and no adjustment will be made to any early redemption payment made on that succeeding business day
|
Contingent monthly coupon:
|
A contingent monthly coupon at an annual rate of at least
20.00% (corresponding to approximately $16.667 per month per security, to be determined on the pricing date) plus any previously
unpaid contingent monthly coupons from any prior observation dates will be paid on the securities on each coupon payment date but
only if the determination closing price of each underlying stock is at or above its respective coupon threshold
level on the related observation date; provided, however, in the case of any such payment of a previously unpaid contingent
monthly coupon, no additional interest shall accrue or be payable in respect of such unpaid contingent monthly coupon from and
after the end of the original interest period for such unpaid contingent monthly coupon. You will not receive such unpaid
contingent monthly coupons if the determination closing price of any underlying stock is less than its respective redemption threshold
level on each subsequent observation date.
If, on any observation date, the determination closing price
of any underlying stock is less than its respective coupon threshold level, no contingent monthly coupon will be paid with respect
to that observation date. It is possible that one or more underlying stocks will remain below their respective
coupon threshold levels for extended periods of time or even throughout the entire 5-year term of the securities so that you will
receive few or no contingent monthly coupons.
|
Downside threshold level:
|
With respect to the SRPT Stock, $
, which is equal to 50% of its initial share price
With respect to the WDC Stock, $ ,
which is equal to 50% of its initial share price
With respect to the KSS Stock, $
, which is equal to 50% of its initial share price
|
Coupon threshold level:
|
With respect to the SRPT Stock, $
, which is equal to 55% of its initial share price
With respect to the WDC Stock, $ ,
which is equal to 55% of its initial share price
With respect to the KSS Stock, $
, which is equal to 55% of its initial share price
|
Payment at maturity:
|
If the securities are not redeemed prior to maturity, investors
will receive a payment at maturity determined as follows:
· If
the final share price of each underlying stock is greater than or equal to its respective downside threshold level:
the stated principal amount and, if the final share price of each underlying stock is also greater than or equal
to its respective coupon threshold level, the contingent monthly coupon with respect to the final observation date and any previously
unpaid contingent monthly coupons from the prior observation dates
· If
the final share price of any underlying stock is less than its respective downside threshold level: (i) the stated
principal amount multiplied by (ii) the share performance factor of the worst performing underlying stock
Under these circumstances, the payment at maturity
will be significantly less than the stated principal amount of $1,000, and will represent a loss of more than 50%, and possibly
all, of your investment.
|
|
Terms continued on the following page:
|
Agent:
|
Morgan Stanley & Co. LLC (“MS & Co.”), an affiliate of MSFL and a wholly owned subsidiary of Morgan Stanley. See “Supplemental information regarding plan of distribution; conflicts of interest.”
|
Estimated value on the pricing date:
|
Approximately $906.50 per security, or within $30.00 of that estimate. See “Investment Summary” beginning on page 4.
|
Commissions and issue price:
|
Price to public
|
Agent’s commissions(1)
|
Proceeds to us(2)
|
Per security
|
$1,000
|
$
|
$
|
Total
|
$
|
$
|
$
|
|
(1)
|
Selected dealers and their financial advisors will
collectively receive from the agent, Morgan Stanley & Co. LLC, a fixed sales commission of $ for each security they sell.
See “Supplemental information regarding plan of distribution; conflicts of interest.” For additional information,
see “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.
|
|
(2)
|
See “Use of proceeds and hedging” on page
34.
|
The
securities involve risks not associated with an investment in ordinary debt securities. See “Risk Factors” beginning
on page 14.
The Securities and Exchange Commission and state securities
regulators have not approved or disapproved these securities, or determined if this document or the accompanying product supplement
and prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The securities are not deposits or saving accounts and are
not insured by the Federal Deposit Insurance Corporation or any other governmental agency or instrumentality, nor are they obligations
of, or guaranteed by, a bank.
You should read this document together with the related product
supplement and prospectus, each of which can be accessed via the hyperlinks below. Please also see “Additional Terms of
the Securities” and “Additional Information About the Securities” at the end of this document.
As used in this document, “we,” “us”
and “our” refer to Morgan Stanley or MSFL, or Morgan Stanley and MSFL collectively, as the context requires.
Product Supplement for Auto-Callable Securities dated November 16, 2017 Prospectus
dated November 16, 2017
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Terms continued from previous page:
|
Redemption determination dates:
|
Beginning after three months, monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject to postponement for non-trading days and certain market disruption events.
|
Redemption threshold level:
|
With respect to the SRPT Stock, $
, which is equal to 86% of its initial share price
With respect to the WDC Stock, $ ,
which is equal to 86% of its initial share price
With respect to the KSS Stock, $
, which is equal to 86% of its initial share price
|
Initial share price:
|
With respect to the SRPT Stock, $ ,
which is its closing price on the pricing date
With respect to the WDC Stock, $
, which is its closing price on the pricing date
With respect to the KSS Stock, $
, which is its closing price on the pricing date
|
Coupon payment dates:
|
Monthly, beginning December 27, 2019, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below; provided that if any such day is not a business day, that coupon payment, if payable, will be made on the next succeeding business day and no adjustment will be made to any coupon payment made on that succeeding business day. The contingent monthly coupon, if any, with respect to the final observation date shall be paid on the maturity date.
|
Observation dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject, independently in the case of each underlying stock, to postponement for non-trading days and certain market disruption events. We also refer to November 21, 2024 as the final observation date.
|
Final share price:
|
With respect to each underlying stock, the closing price of such underlying stock on the final observation date times the adjustment factor on such date
|
Adjustment factor:
|
With respect to each underlying stock, 1.0, subject to adjustment in the event of certain corporate events affecting such underlying stock
|
Worst performing underlying stock:
|
The underlying stock with the largest percentage decrease from the respective initial share price to the respective final share price
|
Share performance factor:
|
Final share price divided by the initial share price
|
CUSIP / ISIN:
|
61769HP90 / US61769HP900
|
Listing:
|
The securities will not be listed on any securities exchange.
|
Observation Dates, Redemption
Determination Dates, Coupon Payment Dates and Early Redemption Dates
Observation Dates / Redemption Determination Dates
|
Coupon Payment Dates / Early Redemption Dates
|
12/23/2019*
|
12/27/2019*
|
1/21/2020*
|
1/24/2020*
|
2/21/2020
|
2/26/2020
|
3/23/2020
|
3/26/2020
|
4/21/2020
|
4/24/2020
|
5/21/2020
|
5/27/2020
|
6/22/2020
|
6/25/2020
|
7/21/2020
|
7/24/2020
|
8/21/2020
|
8/26/2020
|
9/21/2020
|
9/24/2020
|
10/21/2020
|
10/26/2020
|
11/23/2020
|
11/27/2020
|
12/21/2020
|
12/24/2020
|
1/21/2021
|
1/26/2021
|
2/22/2021
|
2/25/2021
|
3/22/2021
|
3/25/2021
|
4/21/2021
|
4/26/2021
|
5/21/2021
|
5/26/2021
|
6/21/2021
|
6/24/2021
|
7/21/2021
|
7/26/2021
|
8/23/2021
|
8/26/2021
|
9/21/2021
|
9/24/2021
|
10/21/2021
|
10/26/2021
|
11/22/2021
|
11/26/2021
|
12/21/2021
|
12/24/2021
|
1/21/2022
|
1/26/2022
|
2/22/2022
|
2/25/2022
|
3/21/2022
|
3/24/2022
|
4/21/2022
|
4/26/2022
|
5/23/2022
|
5/26/2022
|
6/21/2022
|
6/24/2022
|
7/21/2022
|
7/26/2022
|
8/22/2022
|
8/25/2022
|
9/21/2022
|
9/26/2022
|
10/21/2022
|
10/26/2022
|
11/21/2022
|
11/25/2022
|
12/21/2022
|
12/27/2022
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Observation Dates / Redemption Determination Dates
|
Coupon Payment Dates / Early Redemption Dates
|
1/23/2023
|
1/26/2023
|
2/21/2023
|
2/24/2023
|
3/21/2023
|
3/24/2023
|
4/21/2023
|
4/26/2023
|
5/22/2023
|
5/25/2023
|
6/21/2023
|
6/26/2023
|
7/21/2023
|
7/26/2023
|
8/21/2023
|
8/24/2023
|
9/21/2023
|
9/26/2023
|
10/23/2023
|
10/26/2023
|
11/21/2023
|
11/27/2023
|
12/21/2023
|
12/27/2023
|
1/22/2024
|
1/25/2024
|
2/21/2024
|
2/26/2024
|
3/21/2024
|
3/26/2024
|
4/22/2024
|
4/25/2024
|
5/21/2024
|
5/24/2024
|
6/21/2024
|
6/26/2024
|
7/22/2024
|
7/25/2024
|
8/21/2024
|
8/26/2024
|
9/23/2024
|
9/26/2024
|
10/21/2024
|
10/24/2024
|
11/21/2024 (final observation date)
|
11/26/2024 (maturity date)
|
|
|
* The securities are not subject to automatic
early redemption until the third coupon payment date, which is February 26, 2020.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Investment Summary
Contingent Income Auto-Callable Securities
Principal at Risk Securities
Contingent Income Auto-Callable Securities due November 26, 2024,
with 3-month Initial Non-Call Period All Payments on the Securities Based on the Worst Performing of the Common stock of Sarepta
Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation (the “securities”)
do not provide for the regular payment of interest. Instead, the securities will pay a contingent monthly coupon at an annual rate
of at least 20.00% (to be determined on the pricing date) but only if the determination closing price of each underlying
stock is at or above 55% of its respective initial share price, which we refer to as the respective coupon threshold
level, on the related observation date. If the determination closing price of any underlying stock is less than its coupon
threshold level on any observation date, we will pay no coupon for the related monthly period. However,
if the determination closing price of each of the underlying stocks is at or above its respective coupon threshold level on any
subsequent observation date, investors will receive, in addition to the contingent monthly coupon for the related monthly period,
any previously unpaid contingent monthly coupons from prior observation dates. It is possible that the determination closing
price of one or more underlying stocks will remain below their respective coupon threshold levels for extended periods of
time or even throughout the entire 5-year term of the securities so that you will receive few or no contingent monthly coupons
during the entire term of the securities. We refer to these coupons as contingent, because there is no guarantee that you will
receive a coupon payment on any coupon payment date. Even if all of the underlying stocks were to be at or above their respective
coupon threshold levels on some monthly observation dates, one or more underlying stocks may fluctuate below the respective coupon
threshold level(s) on others, and the underlying stocks may not close at or above their respective coupon threshold level on any
subsequent observation date, in which case you will not receive payment of any unpaid previously contingent monthly coupons. In
addition, if the securities have not been automatically called prior to maturity and the final share price of any underlying
stock is less than its respective downside threshold level, which is 50% of the respective initial share price, investors will
be exposed to the decline in the worst performing underlying stock on a 1-to-1 basis, and will receive a payment at maturity that
is less than 50% of the stated principal amount of the securities and could be zero. Accordingly, investors in the securities
must be willing to accept the risk of losing their entire initial investment and also the risk of not receiving any contingent
monthly payments throughout the entire 5-year term of the securities.
Maturity:
|
5 years
|
|
|
Contingent monthly coupon:
|
A contingent monthly coupon at an annual rate of at least
20.00% (corresponding to approximately $16.667 per month per security, to be determined on the pricing date) will be paid on the
securities on each coupon payment date but only if the determination closing price of each underlying stock is at
or above its respective coupon threshold level on the related observation date.
If the contingent monthly coupon is not paid on any coupon
payment date (because the determination closing price of an underlying stock on the related observation date is less than the coupon
threshold level), such unpaid contingent monthly coupon will be paid on a later coupon payment date but only if the determination
closing price of each underlying stock on such later observation date is greater than or equal to the respective coupon threshold
level. You will not receive such unpaid contingent monthly coupon if the determination closing price of any underlying
stock on each subsequent observation date is less than its respective coupon threshold level. If the determination closing
price of any underlying stock on each observation date is less than its respective coupon threshold level, you will not receive
any contingent monthly coupon for the entire term of the securities.
|
Automatic early redemption monthly beginning in
|
Starting in February 2020, if the determination closing price of each underlying stock is greater than or equal to its respective redemption threshold level (equal to 86% of the respective initial share price) on any monthly determination date, beginning on February 21, 2020 (approximately three months after the original issue date), the
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
February 2020:
|
securities will be automatically redeemed for an early redemption payment equal to the stated principal amount plus the contingent monthly coupon with respect to the related observation date and any previously unpaid contingent monthly coupons from prior observation dates.
|
|
|
Payment at maturity:
|
If the securities have not previously been redeemed and the final
share price of each underlying stock is greater than or equal to its respective downside threshold level, the payment
at maturity will be the stated principal amount and, if the final share price of each underlying stock is also greater than or
equal to its respective coupon threshold level, the related contingent monthly coupon and any previously unpaid contingent monthly
coupons from prior observation dates.
If the final share price of any underlying stock is less
than its downside threshold level, investors will receive a payment at maturity based on the decline in the worst performing underlying
stock over the term of the securities. Under these circumstances, the payment at maturity will be less than 50% of the stated principal
amount of the securities and could be zero. Accordingly, investors in the securities must be willing to accept the risk
of losing their entire initial investment.
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
The original issue price of each security is
$1,000. This price includes costs associated with issuing, selling, structuring and hedging the securities, which are borne by
you, and, consequently, the estimated value of the securities on the pricing date will be less than $1,000. We estimate that the
value of each security on the pricing date will be approximately $906.50, or within $30.00 of that estimate. Our estimate of the
value of the securities as determined on the pricing date will be set forth in the final pricing supplement.
What goes into the estimated value on the pricing date?
In valuing the securities on the pricing date,
we take into account that the securities comprise both a debt component and a performance-based component linked to the underlying
stocks. The estimated value of the securities is determined using our own pricing and valuation models, market inputs and assumptions
relating to the underlying stocks, instruments based on the underlying stocks, volatility and other factors including current and
expected interest rates, as well as an interest rate related to our secondary market credit spread, which is the implied interest
rate at which our conventional fixed rate debt trades in the secondary market.
What determines the economic terms of the securities?
In determining the economic terms of the securities,
including the contingent monthly coupon rate, the redemption threshold levels, the coupon threshold levels and the downside threshold
levels, we use an internal funding rate, which is likely to be lower than our secondary market credit spreads and therefore advantageous
to us. If the issuing, selling, structuring and hedging costs borne by you were lower or if the internal funding rate were higher,
one or more terms of the securities would be more favorable to you.
What is the relationship between the estimated value on the
pricing date and the secondary market price of the securities?
The price at which MS & Co. purchases the
securities in the secondary market, absent changes in market conditions, including those related to the underlying stocks, may
vary from, and be lower than, the estimated value on the pricing date, because the secondary market price takes into account our
secondary market credit spread as well as the bid-offer spread that MS & Co. would charge in a secondary market transaction
of this type and other factors. However, because the costs associated with issuing, selling, structuring and hedging the securities
are not fully deducted upon issuance, for a period of up to 6 months following the issue date, to the extent that MS & Co.
may buy or sell the securities in the secondary market, absent changes in market conditions, including those related to the underlying
stocks, and to our secondary market credit spreads, it would do so based on values higher than the estimated value. We expect that
those higher values will also be reflected in your brokerage account statements.
MS & Co. may, but is not obligated to,
make a market in the securities, and, if it once chooses to make a market, may cease doing so at any time.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Key Investment Rationale
The securities do not provide for the regular payment of interest.
Instead, the securities will pay a contingent monthly coupon but only if the determination closing price of each underlying
stock is at or above its respective downside threshold level on the related observation date. The securities have been
designed for investors who are willing to forgo market floating interest rates and risk the loss of principal and accept the risk
of receiving few or no coupon payments for the entire 5-year term of the securities in exchange for an opportunity to earn interest
at a potentially above-market rate if all of the underlying stocks close at or above their respective coupon threshold levels,
unless the securities are redeemed early. The following scenarios are for illustration purposes only to demonstrate how the coupon
and the payment at maturity (if the securities have not previously been redeemed) are calculated, and do not attempt to demonstrate
every situation that may occur. Accordingly, the securities may or may not be redeemed, the contingent coupon may be payable in
none of, or some but not all of, the monthly periods during the 5-year term of the securities, and the payment at maturity may
be less than 50% of the stated principal amount of the securities and may be zero.
Scenario 1: The securities are redeemed prior to maturity
|
This scenario assumes that, prior to early redemption, all of
the underlying stocks close at or above their respective coupon threshold levels on some monthly observation dates, but one or
more underlying stocks close below the respective coupon threshold level(s) on the others. Investors receive the contingent monthly
coupon, as well as any previously unpaid contingent monthly coupons form prior observation dates, for the monthly periods for which
the determination closing price of each underlying stock is greater than or equal to the respective coupon threshold level on the
related observation date.
Starting on February 21, 2020, when all of the underlying stocks
close at or above their respective redemption threshold levels on a monthly redemption determination date, the securities will
be automatically redeemed for the stated principal amount plus the contingent monthly coupon with respect to the related
observation date and any previously unpaid contingent monthly coupons from prior observation dates.
|
Scenario 2: The securities are not redeemed prior to maturity, and investors receive principal back at maturity
|
This scenario assumes that all of the underlying stocks close at or above their respective coupon threshold levels on some monthly observation dates, but one or more underlying stocks close below the respective coupon threshold level(s) on the others, and at least one of the underlying stocks closes below its redemption threshold level on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon, as well as any previously unpaid contingent monthly coupons form prior observation dates, for the monthly periods for which the determination closing price of each underlying stock is greater than or equal to the respective coupon threshold level on the related observation date. On the final observation date, all of the underlying stocks close at or above their respective downside threshold levels. At maturity, investors will receive the stated principal amount and, if the final share price of each underlying stock is also greater than or equal to its respective coupon threshold level, the contingent monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons form prior observation dates, investors will receive the stated principal amount.
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Scenario 3: The securities are not redeemed prior to maturity, and investors suffer a substantial loss of principal at maturity
|
This scenario assumes that all of the underlying stocks close at or above their respective coupon threshold levels on some monthly observation dates, but one or more underlying stocks close below the respective coupon threshold level(s) on the others, and at least one of the underlying stocks closes below its redemption threshold level on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon, as well as any previously unpaid contingent monthly coupons form prior observation dates, for the monthly periods for which the determination closing price of each underlying stock is greater than or equal to the respective coupon threshold level on the related observation date. On the final observation date, one or more underlying stocks close below the respective downside threshold level(s). At maturity, investors will receive an amount equal to the stated principal amount multiplied by the share performance factor of the worst performing underlying stock. Under these circumstances, the payment at maturity will be less than 50% of the stated principal amount and could be zero. No coupon will be paid at maturity in this scenario, and investors will not receive payment of any previously unpaid contingent monthly coupons at maturity.
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
How the Securities Work
The following diagrams illustrate the potential outcomes for
the securities depending on (1) the determination closing prices on each monthly observation date, (2) the determination closing
prices on each monthly redemption determination date and (3) the final share prices. Please see “Hypothetical Examples”
below for an illustration of hypothetical payouts on the securities.
Diagram #1: Contingent Monthly Coupons (Beginning
on the First Coupon Payment Date until Early Redemption or Maturity)
Diagram #2: Automatic Early Redemption (Starting
in February 2020)
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Diagram #3: Payment at Maturity if No Automatic
Early Redemption Occurs
For more information about the payout at
maturity in different hypothetical scenarios, see “Hypothetical Examples” below.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Hypothetical Examples
The following hypothetical examples illustrate how to determine
whether a contingent monthly coupon is paid with respect to an observation date and how to calculate the payment at maturity, if
any, assuming the securities are not redeemed prior to maturity. The following examples are for illustrative purposes only. Whether
you receive a contingent monthly coupon will be determined by reference to the determination closing price of each underlying stock
on each monthly observation date. Whether the securities are redeemed early will be determined by reference to the determination
closing price of each underlying stock on each monthly determination date (beginning approximately three months after the original
issue date) and the payment at maturity, if any, will be determined by reference to the final share price of each underlying stock
on the final determination date. The actual initial share price and downside threshold level for each underlying stock will be
determined on the pricing date. All payments on the securities, if any, are subject to our credit risk. The below examples are
based on the following terms:
Hypothetical Contingent Monthly Coupon:
|
20.00% per annum, (corresponding to approximately $16.667 per
month per security)1
With respect to each coupon payment date, a contingent monthly
coupon plus any previously unpaid monthly coupons from any prior observation dates is paid but only if the determination
closing price of each underlying stock is at or above its respective coupon threshold level on the related observation date.
|
Payment at Maturity (if the securities are not redeemed prior to maturity):
|
If the final share price of each underlying stock is greater
than or equal to its respective downside threshold level: the stated principal amount and, if the final share price of each
underlying stock is also greater than or equal to its respective coupon threshold level, the contingent monthly coupon with respect
to the final observation date and any previously unpaid contingent monthly coupons from the prior observation dates
If the final share price of any underlying stock is less
than its respective downside threshold level: (i) the stated principal amount multiplied by (ii) the share performance
factor of the worst performing underlying stock
|
Stated Principal Amount:
|
$1,000
|
Hypothetical Initial Share Price:
|
With respect to the SRPT Stock: $90.00
With respect to the WDC Stock: $50.00
With respect to the KSS Stock: $50.00
|
Hypothetical Downside Threshold Level:
|
With respect to the SRPT Stock: $45.00, which is 50% of its hypothetical
initial share price
With respect to the WDC Stock: $25.00, which is 50% of its hypothetical
initial share price
With respect to the KSS Stock: $25.00, which is 50% of its hypothetical
initial share price
|
Hypothetical Coupon Threshold Level:
|
With respect to the SRPT Stock: $49.50, which is 55% of its hypothetical
initial share price
With respect to the WDC Stock: $27.50, which is 55% of its hypothetical
initial share price
With respect to the KSS Stock: $27.50, which is 55% of its hypothetical
initial share price
|
1
The actual contingent monthly coupon will be an amount determined by the calculation agent based on
the number of days in the applicable payment period, calculated on a 30/360 day count basis. The hypothetical contingent monthly
coupon of $16.667 is used in these examples for ease of analysis.
How to determine whether a contingent monthly
coupon is payable with respect to an observation date:
|
Determination Closing Price
|
Hypothetical Contingent Monthly Coupon
|
|
SRPT Stock
|
WDC Stock
|
KSS Stock
|
|
1st Monthly Observation Date
|
$105.00 (at or above its coupon threshold level)
|
$70.00 (at or above its coupon threshold level)
|
$75.00 (at or above its coupon threshold level)
|
$16.667
|
2nd Monthly Observation Date
|
$85.00 (at or above its coupon threshold level)
|
$26.00 (below its coupon threshold level)
|
$85.00 (at or above its coupon threshold level)
|
$0
|
3rd Monthly Observation Date
|
$70.00 (at or above its coupon threshold level)
|
$55.00 (at or above its coupon threshold level)
|
$62.50 (at or above its coupon threshold level)
|
$16.667 + $16.667 = $33.334
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
4th Monthly Observation Date
|
$40.00 (below its coupon threshold level)
|
$21.00 (below its coupon threshold level)
|
$22.00 (below its coupon threshold level)
|
$0
|
|
|
|
|
|
On hypothetical observation date 1, each of the underlying stocks
closes at or above its respective coupon threshold level. Therefore, a hypothetical contingent monthly coupon of $16.667 is paid
on the relevant coupon payment date.
On hypothetical observation date 2, two underlying stocks close
at or above their respective coupon threshold levels, but the other underlying stock closes below its respective coupon threshold
level. Therefore, no contingent monthly coupon is paid on the relevant coupon payment date.
On hypothetical observation date 3, each of the underlying stocks
closes at or above its respective coupon threshold level. Therefore, investors receive the hypothetical contingent monthly coupon
with respect to the third observation date as well as the previously unpaid contingent monthly coupon with respect to the second
observation date.
On hypothetical observation date 4, each of the underlying stocks
closes below its respective coupon threshold level, and accordingly no contingent monthly coupon is paid on the relevant coupon
payment date.
You will not receive a contingent monthly coupon on any coupon
payment date if the determination closing price of any underlying stock is below its respective coupon threshold level on the related
observation date.
How to calculate the payment at maturity:
In the following examples, one or more underlying stocks close
below the respective redemption threshold levels on each redemption determination date, and, consequently, the securities are not
automatically redeemed prior to, and remain outstanding until, maturity.
|
Final Share Price
|
Payment at Maturity
|
|
SRPT Stock
|
WDC Stock
|
KSS Stock
|
|
Example 1:
|
$80.00 (at or above its downside threshold level and its coupon threshold level)
|
$60.00 (at or above its downside threshold level and its coupon threshold level)
|
$65.00 (at or above its downside threshold level and its coupon threshold level)
|
$1,000 plus the contingent monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from the prior observation dates
|
Example 2:
|
$18.00 (below its downside threshold level)
|
$45.00 (at or above its downside threshold level)
|
$47.00 (at or above its downside threshold level)
|
$1,000 x share performance factor of the worst performing underlying stock = $1,000 x ($18.00 / $90.00) = $200.00
|
Example 3:
|
$110.00 (at or above its downside threshold level)
|
$80.00 (at or above its downside threshold level)
|
$22.50 (below its downside threshold level)
|
$1,000 x ($22.50 / $50.00) = $450.00
|
Example 4:
|
$27.00 (below its downside threshold level)
|
$20.00 (below its downside threshold level)
|
$22.00 (below its downside threshold level)
|
$1,000 x ($27.00 / $90.00) = $300.00
|
Example 5:
|
$31.50 (below its downside threshold level)
|
$15.00 (below its downside threshold level)
|
$22.00 (below its downside threshold level)
|
$1,000 x ($15.00 / $50.00) = $300.00
|
|
|
|
|
|
In example 1, the final share prices of each of the SRPT Stock,
WDC Stock and KSS Stock are at or above their respective downside threshold levels and coupon threshold levels. Therefore, investors
receive at maturity the stated principal amount of the securities plus the hypothetical contingent monthly coupon with respect
to the final observation date and any previously unpaid contingent monthly coupons from the prior observation dates. Investors
do not participate in the appreciation of any of the underlying stocks.
In example 2, the final share prices of two underlying stocks
are above their respective downside threshold levels, but the final share price of the other underlying stock is below its downside
threshold level. Therefore, investors are exposed to the downside
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
performance of the worst performing underlying stock at maturity
and receive an amount equal to the stated principal amount times the share performance factor of the worst performing underlying
stock.
In example 3, the final share prices of two underlying stocks
are at or above their respective downside threshold levels, but the final share price of the other underlying stock is below its
downside threshold level. Therefore, investors are exposed to the downside performance of the worst performing underlying stock
at maturity and receive at maturity an amount equal to the stated principal amount times the share performance factor of the worst
performing underlying stock.
In examples 4 and 5, the final share prices of all of the underlying
stocks are below their respective downside threshold levels, and investors receive at maturity an amount equal to the stated principal
amount times the share performance factor of the worst performing underlying stock. In example 4, the SRPT Stock has declined
70% from its initial share price to its final share price, the WDC Stock has declined 60% from its initial share price to its final
share price and the KSS Stock has declined 56% from its initial share price to its final share price. Therefore, the payment at
maturity equals the stated principal amount times the share performance factor of the SRPT Stock, which represents the worst
performing underlying stock in this example. In example 5, the SRPT Stock has declined 65% from its initial share price to its
final share price, the WDC Stock has declined 70% from its initial share price to its final share price and the KSS Stock has declined
56% from its initial share price to its final share price. Therefore the payment at maturity equals the stated principal amount
times the share performance factor of the WDC Stock, which represents the worst performing underlying stock in this example.
If the final share price of ANY underlying stock is below
its respective downside threshold level, you will be exposed to the downside performance of the worst performing underlying stock
at maturity, and your payment at maturity will be less than 50% of the stated principal amount per security and could be zero.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Risk Factors
The
following is a list of certain key risk factors for investors in the securities. For further discussion of these and other risks,
you should read the section entitled “Risk Factors” in the accompanying product supplement and prospectus. You should
also consult with your investment, legal, tax, accounting and other advisers in connection with your investment in
the securities.
|
§
|
The securities do not guarantee the return of any principal. The
terms of the securities differ from those of ordinary debt securities in that they do not guarantee the return of any of the principal
amount at maturity. If the securities have not been automatically redeemed prior to maturity and if the final share price of any
underlying stock is less than its downside threshold level of 50% of its initial share price, you will be exposed to the decline
in the closing price of the worst performing underlying stock, as compared to its initial share price, on a 1-to-1 basis, and you
will receive for each security that you hold at maturity an amount equal to the stated principal amount times the share
performance factor of the worst performing underlying stock. In this case, the payment at maturity will be less than 50% of the
stated principal amount and could be zero. You could lose up to your entire investment in the securities.
|
|
§
|
The securities do not provide for the regular payment of interest
and may pay no interest over the entire term of the securities. The terms of the securities differ from those of ordinary
debt securities in that they do not provide for the regular payment of interest. Instead, the securities will pay a contingent
monthly coupon but only if the determination closing price of each underlying stock is at or above 55% of its respective
initial share price, which we refer to as the respective coupon threshold level, on the related observation date. If the determination
closing price of any underlying stock is lower than its coupon threshold level on the relevant observation date for any interest
period, we will pay no coupon on the applicable coupon payment date. However, if the determination closing price of each of the
underlying stocks is at or above its respective coupon threshold level on any subsequent observation date, investors will receive,
in addition to the contingent monthly coupon for the related monthly period, any previously unpaid contingent monthly coupons from
prior observation dates. Nevertheless, it is possible that the determination closing price(s) of one or more underlying stocks
could remain below the respective coupon threshold level(s) for extended periods of time or even throughout the entire 5-year term
of the securities so that you will receive few or no contingent monthly coupons. If you do not earn sufficient contingent coupons
over the term of the securities, the overall return on the securities may be less than the amount that would be paid on a conventional
debt security of ours of comparable maturity.
|
|
§
|
You are exposed to the price risk of all of the underlying stocks,
with respect to both the contingent monthly coupons, if any, and the payment at maturity, if any. Your
return on the securities is not linked to a basket consisting of the underlying stocks. Rather, it will be contingent upon the
independent performance of each underlying stock. Unlike an instrument with a return linked to a basket of underlying assets, in
which risk is mitigated and diversified among all the components of the basket, you will be exposed to the risks related to each
of the underlying stocks. Poor performance by any underlying stock over the term
of the securities may negatively affect your return and will not be offset or mitigated by any positive performance by the other
underlying stocks. To receive any contingent monthly coupons, all
of the underlying stocks must close at or above their respective coupon threshold levels on the
applicable observation date. In addition, if any underlying stock has declined
to below its respective downside threshold level as of the final observation date, you will be fully exposed to
the decline in the worst performing underlying stock over the term of the securities on a 1-to-1 basis, even if the other underlying
stocks have appreciated or have not declined as much. Under this scenario, the value of any such payment will be less than 50%
of the stated principal amount and could be zero. Accordingly, your investment is subject to the price risk of all of the underlying
stocks.
|
|
§
|
The contingent coupon, if any, is based only on the determination closing prices of the underlying stocks on the related
monthly observation date at the end of the related interest period.
Whether the contingent coupon will be paid on any coupon payment date will be determined at the end of the relevant interest period
based on the determination closing price of each underlying stock on the relevant monthly observation date. As a result, you will
not know whether you will receive the contingent coupon on any coupon payment date until near the end of the relevant interest
period. Moreover, because the contingent coupon is based solely on the price of each underlying stock on monthly observation dates,
if the determination closing price of any underlying stock on any observation date is below
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
the
respective coupon threshold level, you will receive no coupon for the related interest period, or any previously unpaid coupons,
even if the price(s) of one or more of the underlying stocks were higher on other days during that interest period.
|
§
|
Investors will not participate in any appreciation in the price of any underlying stock. Investors will not participate
in any appreciation in the price of any underlying stock from its initial share price, and the return on the securities will be
limited to the contingent monthly coupon, if any, that is paid with respect to each observation date on which all determination
closing prices are greater than or equal to their respective coupon threshold levels, if any.
|
|
§
|
The market price will be influenced by many unpredictable factors.
Several factors, many of which are beyond our control, will influence the value of the securities
in the secondary market and the price at which MS & Co. may be willing to purchase or sell the securities in the secondary
market. We expect that generally the level of interest rates available in the market and the prices of the underlying
stocks on any day, including in relation to the respective
coupon threshold levels and downside threshold levels, will affect the value of the securities more than any other factors. Other
factors that may influence the value of the securities include:
|
|
o
|
the trading price and volatility (frequency and magnitude of changes in value) of the underlying stocks,
|
|
o
|
whether the determination closing price of any underlying stock has been below its respective downside threshold level on any
observation date,
|
|
o
|
dividend rates on the underlying stocks,
|
|
o
|
geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underlying stocks
and which may affect the prices of the underlying stocks,
|
|
o
|
the time remaining until the securities mature,
|
|
o
|
interest and yield rates in the market,
|
|
o
|
the availability of comparable instruments,
|
|
o
|
the occurrence of certain events affecting the underlying stock that may or may not require an adjustment to the adjustment
factor, and
|
|
o
|
any actual or anticipated changes in our credit ratings or credit spreads.
|
Generally,
the longer the time remaining to maturity, the more the market price of the securities will be affected by the other factors described
above. Some or all of these factors will influence the price that you will receive if you sell your securities prior to maturity.
For example, you may have to sell your securities at a substantial discount from the stated principal amount of $1,000 per security
if the price of any underlying stock at the time of sale is near or below its coupon threshold level or downside threshold level
or if market interest rates rise.
The
prices of the underlying stocks may be, and have recently been, volatile, and we can give you no assurance that the volatility
will lessen. The prices of the underlying stocks may decrease and be below the respective coupon threshold level(s) on each
observation date so that you will receive no return on your investment, and the price of one or more underlying stocks may decrease
and close below the respective downside threshold level on the final observation date so that you receive a payment at maturity
that is less than 50% of the stated principal amount and could be zero. There can be no assurance that the determination closing
prices of all of the underlying stocks will be at or above their respective coupon threshold levels on any observation date so
that you will receive a coupon payment on the securities for the applicable interest period, or, with respect to the final observation
date, that the closing prices of all of the underlying stocks will be at or above the respective downside threshold levels so that
you do not suffer a significant loss on your initial investment in the securities. See
“Sarepta Therapeutics, Inc. Overview,” “Western Digital Corporation Overview” and “Kohl’s Corporation
Overview” below.
|
§
|
The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads
may adversely affect the market value of the securities. You are dependent on our ability to pay all amounts due on the securities
on each coupon payment date, upon automatic redemption and at maturity and therefore
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
you
are subject to our credit risk. The securities are not guaranteed by any other entity. If we default on our obligations under
the securities, your investment would be at risk and you could lose some or all of your investment. As a result, the market value
of the securities prior to maturity will be affected by changes in the market’s view of our creditworthiness. Any actual
or anticipated decline in our credit ratings or increase in the credit spreads charged by the market for taking our credit risk
is likely to adversely affect the market value of the securities.
|
§
|
As a finance subsidiary, MSFL has no independent operations and will have no independent assets. As a finance subsidiary,
MSFL has no independent operations beyond the issuance and administration of its securities and will have no independent assets
available for distributions to holders of MSFL securities if they make claims in respect of such securities in a bankruptcy, resolution
or similar proceeding. Accordingly, any recoveries by such holders will be limited to those available under the related guarantee
by Morgan Stanley and that guarantee will rank pari passu with all other unsecured, unsubordinated obligations of Morgan
Stanley. Holders will have recourse only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of
securities issued by MSFL should accordingly assume that in any such proceedings they would not have any priority over and should
be treated pari passu with the claims of other unsecured, unsubordinated creditors of Morgan Stanley, including holders
of Morgan Stanley-issued securities.
|
|
§
|
Reinvestment risk. The term
of your investment in the securities may be shortened due to the automatic early redemption feature of the securities. If the securities
are redeemed prior to maturity, you will receive no more contingent monthly coupons and may be forced to invest in a lower interest
rate environment and may not be able to reinvest at comparable terms or returns. However, under no circumstances will the securities
be redeemed in the first three months of the term of the securities.
|
|
§
|
Investing in the securities is not equivalent to investing in the
common stock of Sarepta Therapeutics, Inc., the common stock of Western Digital Corporation or the common stock of Kohl’s
Corporation. Investors in the securities will not participate in any appreciation in the
underlying stocks, and will not have voting rights or rights to receive dividends or other distributions or any other rights with
respect to the underlying stocks. As a result, any return on the securities will not reflect the return you would realize if you
actually owned shares of the underlying stocks and received the dividends paid or distributions made on them.
|
|
§
|
No affiliation with Sarepta Therapeutics, Inc., Western Digital Corporation or Kohl’s
Corporation. Sarepta Therapeutics, Inc., Western Digital Corporation and Kohl’s Corporation are not affiliates
of ours, are not involved with this offering in any way, and have no obligation to consider your interests in taking any corporate
actions that might affect the value of the securities. We have not made any due diligence inquiry with respect to Sarepta Therapeutics,
Inc., Western Digital Corporation or Kohl’s Corporation in connection with this offering.
|
|
§
|
We may engage in business with or involving Sarepta Therapeutics, Inc., Western Digital Corporation or Kohl’s Corporation
without regard to your interests. We or our affiliates may presently or from time to time engage in business with Sarepta Therapeutics,
Inc., Western Digital Corporation or Kohl’s Corporation without regard to your interests and thus may acquire non-public
information about Sarepta Therapeutics, Inc., Western Digital Corporation or Kohl’s Corporation. Neither we nor any of our
affiliates undertakes to disclose any such information to you. In addition, we or our affiliates from time to time have published
and in the future may publish research reports with respect to Sarepta Therapeutics, Inc., Western Digital Corporation or Kohl’s
Corporation, which may or may not recommend that investors buy or hold the underlying stock(s).
|
|
§
|
The antidilution adjustments the calculation agent is required to make do not cover every corporate event that could affect
the underlying stocks. MS & Co., as calculation agent, will adjust the adjustment factors for certain corporate events
affecting the underlying stocks, such as stock splits, stock dividends and extraordinary dividends, and certain other corporate
actions involving the issuers of the underlying stocks, such as mergers. However, the calculation agent will not make an adjustment
for every corporate event that can affect the underlying stocks. For example, the calculation agent is not required to make any
adjustments if the issuers of the underlying stocks or anyone else makes a partial tender or partial exchange offer for the underlying
stocks, nor will adjustments be made following the final observation date. In addition, no adjustments will be made for regular
cash dividends, which are expected to reduce the price of the underlying stocks by the amount of such dividends. If an event occurs
that does not require the
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
calculation
agent to adjust an adjustment factor, such as a regular cash dividend, the market price of the securities and your return on the
securities may be materially and adversely
affected. For example, if the record date for a regular cash dividend were to occur on or shortly before an observation date,
this may decrease the determination closing price of an underlying stock to be less than the respective coupon threshold level
(resulting in no contingent monthly coupon being paid with respect to such date) or the final share price to be less than the
respective downside threshold level (resulting in a loss of a significant portion of all of your investment in the securities),
materially and adversely affecting your return.
|
§
|
The securities will not be listed on any securities exchange and secondary trading may be limited,
and accordingly, you should be willing to hold your securities for the entire 5-year term of the securities. The securities
will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. MS &
Co. may, but is not obligated to, make a market in the securities and, if it once chooses to make a market, may cease doing so
at any time. When it does make a market, it will generally do so for transactions of routine secondary market size at prices based
on its estimate of the current value of the securities, taking into account its bid/offer spread, our credit spreads, market volatility,
the notional size of the proposed sale, the cost of unwinding any related hedging positions, the time remaining to maturity and
the likelihood that it will be able to resell the securities. Even if there is a secondary market, it may not provide enough liquidity
to allow you to trade or sell the securities easily. Since other broker-dealers may not participate significantly in the secondary
market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any,
at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease making a market in the securities, it
is likely that there would be no secondary market for the securities. Accordingly, you should be willing to hold your securities
to maturity.
|
|
§
|
The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate
implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated
with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities,
cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market
prices. Assuming no change in market conditions or any other relevant factors, the prices, if any, at which dealers, including
MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly lower than
the original issue price, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs
that are included in the original issue price and borne by you and because the secondary market prices will reflect our secondary
market credit spreads and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well
as other factors.
|
The inclusion of the costs of issuing,
selling, structuring and hedging the securities in the original issue price and the lower rate we are willing to pay as issuer
make the economic terms of the securities less favorable to you than they otherwise would be.
However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 6 months
following the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes
in market conditions, including those related to the underlying stocks, and to our secondary market credit spreads, it would do
so based on values higher than the estimated value, and we expect that those higher values will also be reflected in your brokerage
account statements.
|
§
|
The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from
those of other dealers and is not a maximum or minimum secondary market price. These pricing and valuation models are proprietary
and rely in part on subjective views of certain market inputs and certain assumptions about future events, which may prove to be
incorrect. As a result, because there is no market-standard way to value these types of securities, our models may yield a higher
estimated value of the securities than those generated by others, including other dealers in the market, if they attempted to value
the securities. In addition, the estimated value on the pricing date does not represent a minimum or maximum price at which dealers,
including MS & Co., would be willing to purchase your securities in the secondary market (if any exists) at any time. The value
of your securities at any time after the date of this document will vary based on many factors that cannot be predicted with
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
accuracy,
including our creditworthiness and changes in market conditions. See also “The market price will be influenced by many unpredictable
factors” above.
|
§
|
Hedging and trading activity by our affiliates could potentially affect the value of the securities. One or more of
our affiliates and/or third-party dealers expect to carry out hedging activities related to the securities (and to other instruments
linked to the underlying stocks), including trading in the underlying stocks. Some of our affiliates also trade the underlying
stocks and other financial instruments related to the underlying stocks on a regular basis as part of their general broker-dealer
and other businesses. As a result, these entities may be unwinding or adjusting hedge positions during the term of the securities,
and the hedging strategy may involve greater and more frequent dynamic adjustments to the hedge as the final observation date approaches.
Any of these hedging or trading activities on or prior to the pricing date could potentially increase the initial share price of
an underlying stock, and, therefore, could potentially increase (i) the value at or above which such underlying stock must close
on the redemption determination dates so that the securities are redeemed prior to maturity for the early redemption payment (depending
also on the performance of the other underlying stocks), (ii) the coupon threshold level for such underlying stock, which is the
value at or above which the underlying stock must close on the observation dates so that you receive a contingent monthly coupon
on the securities (depending also on the performance of the other underlying stocks), and (iii) the downside threshold level for
such underlying stock, which is the value at or above which such underlying stock must close on the final observation date, so
that you are not exposed to the negative performance of the worst performing underlying stock at maturity (depending also on the
performance of the other underlying stocks). Additionally, such hedging or trading activities during the term of the securities
could potentially affect the value of any underlying stock on the redemption determination dates and the observation dates, and,
accordingly, whether we redeem the securities prior to maturity, whether we pay a contingent monthly coupon on the securities and
the amount of cash you will receive at maturity, if any (depending also on the performance of the other underlying stocks).
|
|
§
|
The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect
to the securities. As calculation agent, MS & Co. will determine the initial share prices, the redemption threshold levels,
the coupon threshold levels, the downside threshold levels, the final share prices, the payment at maturity, if any, whether you
receive a contingent monthly coupon on each coupon payment date and/or at maturity, whether the securities will be redeemed on
any early redemption date, whether a market disruption event has occurred and whether to make any adjustments to the adjustment
factors. Moreover, certain determinations made by MS & Co., in its capacity as calculation agent, may require it to exercise
discretion and make subjective judgments, such as with respect to the occurrence or non-occurrence of market disruption events
and certain adjustments to the adjustment factors. These potentially subjective determinations may affect the payout to you upon
an automatic early redemption or at maturity, if any. For further information regarding these types of determinations, see “Description
of Auto-Callable Securities—Auto-Callable Securities Linked to Underlying Shares” and “—Calculation Agent
and Calculations” and related definitions in the accompanying product supplement. In addition, MS & Co. has determined
the estimated value of the securities on the pricing date.
|
|
§
|
The U.S. federal income tax consequences of an investment in the securities are uncertain. There is no direct legal
authority as to the proper treatment of the securities for U.S. federal income tax purposes, and, therefore, significant aspects
of the tax treatment of the securities are uncertain.
|
Please read the discussion under
“Additional Information—Tax considerations” in this document concerning the U.S. federal income tax consequences
of an investment in the securities. We intend to treat a security for U.S. federal income tax purposes as a single financial contract
that provides for a coupon that will be treated as gross income to you at the time received or accrued, in accordance with your
regular method of tax accounting. Under this treatment, the ordinary income treatment of the coupon payments, in conjunction with
the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could result in adverse
tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations. We do not
plan to request a ruling from the Internal Revenue Service (the “IRS”) regarding the tax treatment of the securities,
and the IRS or a court may not agree with the tax treatment described herein. If the IRS were successful in asserting an alternative
treatment for the securities, the timing and character of income or loss on the securities might differ significantly from the
tax treatment described herein. For example, under one possible treatment, the IRS could seek to recharacterize the securities
as
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
debt instruments. In that event,
U.S. Holders (as defined below) would be required to accrue into income original issue discount on the securities every year at
a “comparable yield” determined at the time of issuance (as adjusted based on the difference, if any, between the actual
and the projected amount of any contingent payments on the securities) and recognize all income and gain in respect of the securities
as ordinary income. The risk that financial instruments providing for buffers, triggers or similar downside protection features,
such as the securities, would be recharacterized as debt is greater than the risk of recharacterization for comparable financial
instruments that do not have such features.
Non-U.S. Holders (as defined
below) should note that we currently intend to withhold on any coupon paid to Non-U.S. Holders generally at a rate of 30%, or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision, and will
not be required to pay any additional amounts with respect to amounts withheld.
In 2007, the U.S. Treasury Department
and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts”
and similar instruments. While it is not clear whether the securities would be viewed as similar to the prepaid forward contracts
described in the notice, it is possible that any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive
effect. The notice focuses on a number of issues, the most relevant of which for holders of the securities are the character and
timing of income or loss and the degree, if any, to which income realized by non-U.S. investors should be subject to withholding
tax. Both U.S. and Non-U.S. Holders should consult their tax advisers regarding the U.S. federal income tax consequences of an
investment in the securities, including possible alternative treatments, the issues presented by this notice and any tax consequences
arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Sarepta Therapeutics,
Inc. Overview
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The
SRPT Stock is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Information provided
to or filed with the Securities and Exchange Commission by Sarepta Therapeutics, Inc. pursuant to the Exchange Act can be located
by reference to the Securities and Exchange Commission file number 001-14895 through the Securities and Exchange Commission’s
website at www.sec.gov. In addition, information regarding Sarepta Therapeutics, Inc. may be obtained from other sources including,
but not limited to, press releases, newspaper articles and other publicly disseminated documents. Neither the issuer nor the
agent makes any representation that such publicly available documents or any other publicly available information regarding the
issuer of the SRPT Stock is accurate or complete.
Information as of market close on November 4, 2019:
Bloomberg Ticker Symbol:
|
SRPT
|
Exchange:
|
Nasdaq
|
Current Stock Price:
|
$90.81
|
52 Weeks Ago:
|
$139.53
|
52 Week High (on 7/15/2019):
|
$156.91
|
52 Week Low (on 9/26/2019):
|
$72.81
|
Current Dividend Yield:
|
N/A
|
|
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the SRPT Stock for each quarter from January 1, 2016 through November
4, 2019. The closing price of the SRPT Stock on November 4, 2019 was $90.81. The associated graph shows the closing prices of the
SRPT Stock for each day from January 1, 2014 through November 4, 2019. We obtained the information in the table and graph below
from Bloomberg Financial Markets, without independent verification. The historical performance of the SRPT Stock should not be
taken as an indication of its future performance, and no assurance can be given as to the price of the SRPT Stock at any time,
including on the redemption determination dates or the observation dates.
Common Stock of Sarepta Therapeutics, Inc. (CUSIP 002346104)
|
High ($)
|
Low ($)
|
Dividends ($)
|
2016
|
|
|
|
First Quarter
|
38.07
|
10.74
|
-
|
Second Quarter
|
23.35
|
11.02
|
-
|
Third Quarter
|
62.24
|
20.25
|
-
|
Fourth Quarter
|
62.35
|
27.43
|
-
|
2017
|
|
|
|
First Quarter
|
37.89
|
27.67
|
-
|
Second Quarter
|
36.72
|
28.41
|
-
|
Third Quarter
|
47.15
|
33.89
|
-
|
Fourth Quarter
|
56.75
|
47.64
|
-
|
2018
|
|
|
|
First Quarter
|
82.27
|
54.02
|
-
|
Second Quarter
|
153.69
|
71.74
|
-
|
Third Quarter
|
161.51
|
115.31
|
-
|
Fourth Quarter
|
148.76
|
97.32
|
-
|
2019
|
|
|
|
First Quarter
|
151.68
|
106.67
|
-
|
Second Quarter
|
151.95
|
112.21
|
-
|
Third Quarter
|
156.91
|
72.81
|
-
|
Fourth Quarter (through November 4, 2019)
|
90.81
|
76.53
|
-
|
We make no representation as to the amount
of dividends, if any, that Sarepta Therapeutics, Inc. may pay in the future. In any event, as an investor in the Contingent Income
Auto-Callable Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of Sarepta
Therapeutics, Inc.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Common Stock of Sarepta Therapeutics, Inc. – Daily Closing Prices
January 1, 2014 to November 4, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 50% of the initial share price and the black solid line indicates the hypothetical coupon threshold
level of 55% of the initial share price, in each case assuming the closing price of the underlying stock on November 4, 2019 were
the initial share price.
This document relates only to the securities
offered hereby and does not relate to the SRPT Stock or other securities of Sarepta Therapeutics, Inc. We have derived all disclosures
contained in this document regarding Sarepta Therapeutics, Inc. stock from the publicly available documents described above. In
connection with the offering of the securities, neither we nor the agent has participated in the preparation of such documents
or made any due diligence inquiry with respect to Sarepta Therapeutics, Inc. Neither we nor the agent makes any representation
that such publicly available documents or any other publicly available information regarding Sarepta Therapeutics, Inc. is accurate
or complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that
would affect the accuracy or completeness of the publicly available documents described above) that would affect the trading price
of the SRPT Stock (and therefore the price of the SRPT Stock at the time we price the securities) have been publicly disclosed.
Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning Sarepta
Therapeutics, Inc. could affect the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates
makes any representation to you as to the performance of the SRPT Stock.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Western Digital Corporation
Overview
Western Digital Corporation is a developer, manufacturer and
provider of data storage devices for the information technology industry. The WDC Stock is registered under the Exchange Act. Information
provided to or filed with the Securities and Exchange Commission by Western Digital Corporation pursuant to the Exchange Act can
be located by reference to the Securities and Exchange Commission file number 001-08703 through the Securities and Exchange Commission’s
website at .www.sec.gov. In addition, information regarding Western Digital Corporation may be obtained from other sources
including, but not limited to, press releases, newspaper articles and other publicly disseminated documents. Neither the issuer
nor the agent makes any representation that such publicly available documents or any other publicly available information regarding
the issuer of the WDC Stock is accurate or complete.
Information as of market close on November 4, 2019:
Bloomberg Ticker Symbol:
|
WDC
|
Exchange:
|
Nasdaq
|
Current Stock Price:
|
$54.96
|
52 Weeks Ago:
|
$48.36
|
52 Week High (on 9/12/2019):
|
$64.70
|
52 Week Low (on 12/24/2018):
|
$35.06
|
Current Dividend Yield:
|
3.64%
|
|
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the WDC Stock for each quarter from January 1, 2016 through November 4,
2019. The closing price of the WDC Stock on November 4, 2019 was $54.96. The associated graph shows the closing prices of the WDC
Stock for each day from January 1, 2014 through November 4, 2019. We obtained the information in the table and graph below from
Bloomberg Financial Markets, without independent verification. The historical performance of the WDC Stock should not be taken
as an indication of its future performance, and no assurance can be given as to the price of the WDC Stock at any time, including
on the redemption determination dates or the observation dates.
Common Stock of Western Digital Corporation (CUSIP 958102105)
|
High ($)
|
Low ($)
|
Dividends ($)
|
2016
|
|
|
|
First Quarter
|
60.40
|
40.10
|
0.50
|
Second Quarter
|
50.81
|
35.44
|
0.50
|
Third Quarter
|
58.86
|
43.17
|
0.50
|
Fourth Quarter
|
70.35
|
53.07
|
0.50
|
2017
|
|
|
|
First Quarter
|
83.75
|
69.43
|
0.50
|
Second Quarter
|
93.67
|
82.14
|
0.50
|
Third Quarter
|
95.01
|
79.19
|
0.50
|
Fourth Quarter
|
92.91
|
77.11
|
0.50
|
2018
|
|
|
|
First Quarter
|
106.45
|
80.09
|
0.50
|
Second Quarter
|
92.51
|
76.77
|
0.50
|
Third Quarter
|
80.08
|
54.98
|
0.50
|
Fourth Quarter
|
58.36
|
35.06
|
0.50
|
2019
|
|
|
|
First Quarter
|
52.61
|
35.65
|
0.50
|
Second Quarter
|
55.39
|
36.24
|
0.50
|
Third Quarter
|
64.70
|
47.94
|
0.50
|
Fourth Quarter (through November 4, 2019)
|
62.79
|
51.65
|
-
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
We make no representation as to the amount
of dividends, if any, that Western Digital Corporation may pay in the future. In any event, as an investor in the Contingent Income
Auto-Callable Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of Western
Digital Corporation.
Common Stock of Western Digital Corporation – Daily Closing Prices
January 1, 2014 to November 4, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 50% of the initial share price and the black solid line indicates the hypothetical coupon threshold
level of 55% of the initial share price, in each case assuming the closing price of the underlying stock on November 4, 2019 were
the initial share price.
This document relates only to the securities
offered hereby and does not relate to the WDC Stock or other securities of Western Digital Corporation. We have derived all disclosures
contained in this document regarding Western Digital Corporation stock from the publicly available documents described above. In
connection with the offering of the securities, neither we nor the agent has participated in the preparation of such documents
or made any due diligence inquiry with respect to Western Digital Corporation. Neither we nor the agent makes any representation
that such publicly available documents or any other publicly available information regarding Western Digital Corporation is accurate
or complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that
would affect the accuracy or completeness of the publicly available documents described above) that would affect the trading price
of the WDC Stock (and therefore the price of the WDC Stock at the time we price the securities) have been publicly disclosed. Subsequent
disclosure of any such events or the disclosure of or failure to disclose material future events concerning Western Digital Corporation
could affect the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates
makes any representation to you as to the performance of the WDC Stock.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Kohl’s Corporation Overview
Kohl’s Corporation operates stores and a website selling
proprietary and national brand apparel, footwear, accessories, beauty and home products. The KSS Stock is registered under the
Exchange Act. Information provided to or filed with the Securities and Exchange Commission by Kohl’s Corporation pursuant
to the Exchange Act can be located by reference to the Securities and Exchange Commission file number 001-11084 through the Securities
and Exchange Commission’s website at .www.sec.gov. In addition, information regarding Kohl’s Corporation may be obtained
from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents.
Neither the issuer nor the agent makes any representation that such publicly available documents or any other publicly available
information regarding the issuer of the KSS Stock is accurate or complete.
Information as of market close on November 4, 2019:
Bloomberg Ticker Symbol:
|
KSS
|
Exchange:
|
NYSE
|
Current Stock Price:
|
$54.09
|
52 Weeks Ago:
|
$79.20
|
52 Week High (on 11/9/2018):
|
$81.97
|
52 Week Low (on 8/15/2019):
|
$44.27
|
Current Dividend Yield:
|
4.95%
|
|
|
The following table sets forth the published
high and low closing prices of, as well as dividends on, the KSS Stock for each quarter from January 1, 2016 through November 4,
2019. The closing price of the KSS Stock on November 4, 2019 was $54.09. The associated graph shows the closing prices of the KSS
Stock for each day from January 1, 2014 through November 4, 2019. We obtained the information in the table and graph below from
Bloomberg Financial Markets, without independent verification. The historical performance of the KSS Stock should not be taken
as an indication of its future performance, and no assurance can be given as to the price of the KSS Stock at any time, including
on the redemption determination dates or the observation dates.
Common Stock of Kohl’s Corporation (CUSIP 500255104)
|
High ($)
|
Low($)
|
Dividends ($)
|
2016
|
|
|
|
First Quarter
|
51.13
|
39.69
|
0.50
|
Second Quarter
|
46.13
|
34.49
|
0.50
|
Third Quarter
|
46.08
|
36.74
|
0.50
|
Fourth Quarter
|
59.43
|
42.69
|
0.50
|
2017
|
|
|
|
First Quarter
|
51.88
|
37.41
|
0.55
|
Second Quarter
|
40.76
|
35.32
|
0.55
|
Third Quarter
|
46.34
|
36.63
|
0.55
|
Fourth Quarter
|
56.87
|
40.69
|
0.55
|
2018
|
|
|
|
First Quarter
|
68.83
|
54.36
|
0.61
|
Second Quarter
|
78.32
|
58.38
|
0.61
|
Third Quarter
|
82.05
|
69.13
|
0.61
|
Fourth Quarter
|
81.97
|
59.40
|
0.61
|
2019
|
|
|
|
First Quarter
|
71.33
|
64.37
|
0.67
|
Second Quarter
|
75.48
|
45.98
|
0.67
|
Third Quarter
|
53.86
|
44.27
|
0.67
|
Fourth Quarter (through November 4, 2019)
|
54.09
|
46.18
|
-
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
We make no representation as to the amount
of dividends, if any, that Kohl’s Corporation may pay in the future. In any event, as an investor in the Contingent Income
Auto-Callable Securities, you will not be entitled to receive dividends, if any, that may be payable on the common stock of Kohl’s
Corporation.
Common Stock of Kohl’s Corporation – Daily Closing Prices
January 1, 2014 to November 4, 2019
|
|
* The red solid line indicates the hypothetical
downside threshold level of 50% of the initial share price and the black solid line indicates the hypothetical coupon threshold
level of 55% of the initial share price, in each case assuming the closing price of the underlying stock on November 4, 2019 were
the initial share price.
This document relates only to the securities
offered hereby and does not relate to the KSS Stock or other securities of Kohl’s Corporation. We have derived all disclosures
contained in this document regarding Kohl’s Corporation stock from the publicly available documents described above. In connection
with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any
due diligence inquiry with respect to Kohl’s Corporation. Neither we nor the agent makes any representation that such publicly
available documents or any other publicly available information regarding Kohl’s Corporation is accurate or complete. Furthermore,
we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy
or completeness of the publicly available documents described above) that would affect the trading price of the KSS Stock (and
therefore the price of the KSS Stock at the time we price the securities) have been publicly disclosed. Subsequent disclosure of
any such events or the disclosure of or failure to disclose material future events concerning Kohl’s Corporation could affect
the value received with respect to the securities and therefore the value of the securities.
Neither the issuer nor any of its affiliates makes any representation
to you as to the performance of the KSS Stock.
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Additional Terms of the Securities
Please read this information in conjunction with the summary
terms on the front cover of this document.
Additional Terms:
|
If the terms described herein are inconsistent with those described in the accompanying product supplement or prospectus, the terms described herein shall control.
|
Interest period:
|
The monthly period from and including the original issue date (in the case of the first interest period) or the previous scheduled coupon payment date, as applicable, to but excluding the following scheduled coupon payment date, with no adjustment for any postponement thereof.
|
Record date:
|
The record date for each coupon payment date shall be the date one business day prior to such scheduled coupon payment date; provided, however, that any coupon payable at maturity (or upon early redemption) shall be payable to the person to whom the payment at maturity or early redemption payment, as the case may be, shall be payable.
|
Underlying stock:
|
The accompanying product supplement refers to the underlying stock as the “underlying shares.”
|
Underlying stock issuer:
|
With respect to the SRPT Stock, Sarepta Therapeutics, Inc.
With respect to the WDC Stock, Western Digital Corporation
With respect to the KSS Stock, Kohl’s Corporation
The accompanying product supplement refers to each underlying
stock issuer as an “underlying company.”
|
Downside threshold level:
|
The accompanying product supplement refers to the downside threshold level as the “trigger level.”
|
Day count convention:
|
Interest will be computed on the basis of a 360-day year of twelve 30-day months.
|
Postponement of coupon payment dates (including the maturity date) and early redemption dates:
|
If any observation date or redemption determination date is postponed due to a non-trading day or certain market disruption events with respect to any underlying stock so that it falls less than two business days prior to the scheduled coupon payment date (including the maturity date) or early redemption date, as applicable, the coupon payment date (or maturity date) or the early redemption date will be postponed to the second business day following that final observation date or redemption determination date as postponed with respect to any underlying stock, and no adjustment will be made to any coupon payment, early redemption payment or payment at maturity made on that postponed date.
|
Antidilution adjustments:
|
The following replaces in its entirety the portion of the
section entitled “Antidilution Adjustments” in the accompanying product supplement for auto-callable securities from
the start of paragraph 5 to the end of such section.
5. If, with respect to one or more of the underlying stocks,
(i) there occurs any reclassification or change of such underlying stock, including, without limitation, as a result of the issuance
of any tracking stock by the underlying stock issuer for such underlying stock, (ii) such underlying stock issuer or any surviving
entity or subsequent surviving entity of such underlying stock issuer (the “successor corporation”) has been subject
to a merger, combination or consolidation and is not the surviving entity, (iii) any statutory exchange of securities of such underlying
stock issuer or any successor corporation with another corporation occurs (other than pursuant to clause (ii) above), (iv) such
underlying stock issuer is liquidated, (v) such underlying stock issuer issues to all of its shareholders equity securities of
an issuer other than such underlying stock issuer (other than in a transaction described in clause (ii), (iii) or (iv) above) (a
“spin-off event”) or (vi) a tender or exchange offer or going-private transaction is consummated for all the outstanding
shares of such underlying stock (any such event in clauses (i) through (vi), a “reorganization event”), the method
of determining whether an early redemption has occurred and the amount payable upon an early redemption date or at maturity for
each security will be as follows:
· Upon
any redemption determination date following the effective date of a reorganization event and prior to the final observation date:
If the exchange property value (as defined below) is greater than or equal to the respective redemption threshold level, and the
determination closing price (or exchange property value, if applicable) of each other underlying stock is also greater than or
equal to its redemption threshold level, the securities will be automatically redeemed for an early redemption payment.
· Upon
the final observation date, if the securities have not previously been automatically
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
redeemed: You will receive for
each security that you hold a payment at maturity equal to:
Ø If
the exchange property value on the final observation date is greater than or equal to the respective downside threshold level,
and the final share price of each other underlying stock (or exchange property value, as applicable) is also greater than or equal
to its respective downside threshold level: the stated principal amount and, if the exchange property value on the final observation
date is also greater than or equal to the respective coupon threshold level, and the final share price of each other underlying
stock (or exchange property value, as applicable) is also greater than or equal to its respective coupon threshold level, the contingent
monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from the prior observation
dates.
Ø If
the exchange property value on the final observation date is less than the respective downside threshold level, or if the final
share price (or exchange property value, if applicable) of any other underlying stock is less than its respective downside threshold
level:
Ø If
the worst performing underlying stock has not undergone a reorganization event as described in paragraph 5 above: (i) the stated
principal amount multiplied by (ii) the share performance factor of the worst performing underlying stock.
Ø If
the worst performing underlying stock has undergone a reorganization event as described in paragraph 5 above: (i) the stated
principal amount multiplied by (ii) the share performance factor of the worst performing underlying stock. For purposes of determining
the share performance factor of the worst performing underlying stock, the final share price of such worst performing underlying
stock will be deemed to equal the per-share cash value, determined as of the final observation date, of the securities, cash or
any other assets distributed to holders of the worst performing underlying stock in or as a result of any such reorganization event,
including (A) in the case of the issuance of tracking stock, the reclassified share of such worst performing underlying stock,
(B) in the case of a spin-off event, the share of such worst performing underlying stock with respect to which the spun-off security
was issued, and (C) in the case of any other reorganization event where such worst performing underlying stock continues to be
held by the holders receiving such distribution, such worst performing underlying stock (collectively, the “exchange property”).
Following the effective date of a reorganization event, the contingent
monthly coupon, as well as any previously unpaid contingent monthly coupons, will be payable for each observation date on which
the exchange property value is greater than or equal to the coupon threshold level and the determination closing price (or exchange
property value, as applicable) of each other underlying stock is also greater than or equal to its coupon threshold level.
If exchange property includes a cash component,
investors will not receive any interest accrued on such cash component. In the event exchange property consists of securities,
those securities will, in turn, be subject to the antidilution adjustments set forth in paragraphs 1 through 5.
For purposes of determining whether or not
the exchange property value is less than the initial share price, less than the coupon threshold level or less than the downside
threshold level, or for determining the worst performing underlying stock, “exchange property value” means (x) for
any cash received in any reorganization event, the value, as determined by the calculation agent, as of the date of receipt, of
such cash received for one share of such underlying stock, as adjusted by the adjustment factor at the time of such reorganization
event, (y) for any property other than cash or securities received in any such reorganization event, the market value, as determined
by the calculation agent in its sole discretion, as of the date of receipt, of such exchange property received for one share of
such underlying stock, as adjusted by the adjustment factor at the time of such reorganization event and (z) for any security received
in any such reorganization event, an amount equal to the determination closing price, as of the day on which the exchange property
value is determined, per share of such security multiplied by the quantity of such security received for each share of such underlying
stock, as adjusted by the adjustment factor at the time of such reorganization event.
For purposes of paragraph 5 above, in the case
of a consummated tender or exchange offer
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
or going-private transaction involving consideration
of particular types, exchange property shall be deemed to include the amount of cash or other property delivered by the offeror
in the tender or exchange offer (in an amount determined on the basis of the rate of exchange in such tender or exchange offer
or going-private transaction). In the event of a tender or exchange offer or a going-private transaction with respect to exchange
property in which an offeree may elect to receive cash or other property, exchange property shall be deemed to include the kind
and amount of cash and other property received by offerees who elect to receive cash.
Following the occurrence of any reorganization
event referred to in paragraph 5 above, all references in this offering document and in the related product supplement with respect
to the securities to such “underlying stock” shall be deemed to refer to the exchange property and references to a
“share” or “shares” of such underlying stock shall be deemed to refer to the applicable unit or units of
such exchange property, unless the context otherwise requires.
No adjustment to the adjustment factor will
be required unless such adjustment would require a change of at least 0.1% in the adjustment factor then in effect. The adjustment
factor resulting from any of the adjustments specified above will be rounded to the nearest one hundred-thousandth, with five one-millionths
rounded upward. Adjustments to the adjustment factor will be made up to the close of business on the final observation date.
No adjustments to the adjustment factor or
method of calculating the adjustment factor will be required other than those specified above. The adjustments specified above
do not cover all events that could affect the determination closing price or the final share price of such underlying stock, including,
without limitation, a partial tender or exchange offer for such underlying stock.
The calculation agent shall be solely responsible
for the determination and calculation of any adjustments to the adjustment factor or method of calculating the adjustment factor
and of any related determinations and calculations with respect to any distributions of stock, other securities or other property
or assets (including cash) in connection with any corporate event described in paragraphs 1 through 5 above, and its determinations
and calculations with respect thereto shall be conclusive in the absence of manifest error.
The calculation agent will provide information as to any adjustments
to the adjustment factor or to the method of calculating the amount payable at maturity of the securities made pursuant to paragraph
5 above upon written request by any investor in the securities.
|
Trustee:
|
The Bank of New York Mellon
|
Calculation agent:
|
MS & Co.
|
Issuer notices to registered security holders, the trustee and the depositary:
|
In the event that the maturity date is postponed due to postponement
of the final observation date, the issuer shall give notice of such postponement and, once it has been determined, of the date
to which the maturity date has been rescheduled (i) to each registered holder of the securities by mailing notice of such postponement
by first class mail, postage prepaid, to such registered holder’s last address as it shall appear upon the registry books,
(ii) to the trustee by facsimile, confirmed by mailing such notice to the trustee by first class mail, postage prepaid, at its
New York office and (iii) to The Depository Trust Company (the “depositary”) by telephone or facsimile confirmed by
mailing such notice to the depositary by first class mail, postage prepaid. Any notice that is mailed to a registered holder of
the securities in the manner herein provided shall be conclusively presumed to have been duly given to such registered holder,
whether or not such registered holder receives the notice. The issuer shall give such notice as promptly as possible, and in no
case later than (i) with respect to notice of postponement of the maturity date, the business day immediately preceding the scheduled
maturity date and (ii) with respect to notice of the date to which the maturity date has been rescheduled, the business day immediately
following the final observation date as postponed.
In the event that the securities are subject to early redemption,
the issuer shall, (i) on the business day following the applicable redemption determination date, give notice of the early redemption
and the early redemption payment, including specifying the payment date of the amount due upon the early redemption, (x) to each
registered holder of the securities by mailing notice of such early redemption by first class mail, postage prepaid, to such registered
holder’s last address as it shall appear upon the registry books, (y) to the trustee by facsimile confirmed by mailing such
notice to the trustee by first class mail, postage prepaid, at its New York office and (z) to the depositary by telephone or facsimile
confirmed by mailing such
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
notice to the depositary by first class mail, postage prepaid,
and (ii) on or prior to the early redemption date, deliver the aggregate cash amount due with respect to the securities to the
trustee for delivery to the depositary, as holder of the securities. Any notice that is mailed to a registered holder of the securities
in the manner herein provided shall be conclusively presumed to have been duly given to such registered holder, whether or not
such registered holder receives the notice. This notice shall be given by the issuer or, at the issuer’s request, by the
trustee in the name and at the expense of the issuer, with any such request to be accompanied by a copy of the notice to be given.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash to be delivered as contingent monthly coupon, if any, with respect to each security on or prior to 10:30 a.m. (New York City
time) on the business day preceding each coupon payment date, and (ii) deliver the aggregate cash amount due, if any, with respect
to the contingent monthly coupon to the trustee for delivery to the depositary, as holder of the securities, on the applicable
coupon payment date.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash, if any, to be delivered with respect to the securities, on or prior to 10:30 a.m. (New York City time) on the business day
preceding the maturity date, and (ii) deliver the aggregate cash amount due with respect to the securities, if any, to the trustee
for delivery to the depositary, as holder of the securities, on the maturity date.
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
Additional Information About the Securities
Additional Information:
|
Minimum ticketing size:
|
$1,000 / 1 security
|
Tax considerations:
|
Prospective investors should note that the discussion under
the section called “United States Federal Taxation” in the accompanying product supplement does not apply to the securities
issued under this document and is superseded by the following discussion.
The following is a general discussion of the material U.S. federal
income tax consequences and certain estate tax consequences of the ownership and disposition of the securities. This discussion
applies only to investors in the securities who:
· purchase
the securities in the original offering; and
· hold
the securities as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the “Code”).
This discussion does not describe all of the
tax consequences that may be relevant to a holder in light of the holder’s particular circumstances or to holders subject
to special rules, such as:
· certain
financial institutions;
· insurance
companies;
· certain
dealers and traders in securities or commodities;
· investors
holding the securities as part of a “straddle,” wash sale, conversion transaction, integrated transaction or constructive
sale transaction;
· U.S.
Holders (as defined below) whose functional currency is not the U.S. dollar;
· partnerships
or other entities classified as partnerships for U.S. federal income tax purposes;
· regulated
investment companies;
· real
estate investment trusts; or
· tax-exempt
entities, including “individual retirement accounts” or “Roth IRAs” as defined in Section 408 or 408A of
the Code, respectively.
If an entity that is classified as a partnership
for U.S. federal income tax purposes holds the securities, the U.S. federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. If you are a partnership holding the securities or a partner
in such a partnership, you should consult your tax adviser as to the particular U.S. federal tax consequences of holding and disposing
of the securities to you.
As the law applicable to the U.S. federal income
taxation of instruments such as the securities is technical and complex, the discussion below necessarily represents only a general
summary. The effect of any applicable state, local or non-U.S. tax laws is not discussed, nor are any alternative minimum tax consequences
or consequences resulting from the Medicare tax on investment income. Moreover, the discussion below does not address the consequences
to taxpayers subject to special tax accounting rules under Section 451(b) of the Code.
This discussion is based on the Code, administrative
pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, all as of the date hereof, changes to
any of which subsequent to the date hereof may affect the tax consequences described herein. Persons considering the purchase of
the securities should consult their tax advisers with regard to the application of the U.S. federal income tax laws to their particular
situations as well as any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
General
Due to the absence of statutory, judicial or
administrative authorities that directly address the treatment of the securities or instruments that are similar to the securities
for U.S. federal
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
income tax purposes, no assurance can be given
that the IRS or a court will agree with the tax treatment described herein. We intend to treat a security for U.S. federal income
tax purposes as a single financial contract that provides for a coupon that will be treated as gross income to you at the time
received or accrued in accordance with your regular method of tax accounting. In the opinion of our counsel, Davis Polk & Wardwell
LLP, this treatment of the securities is reasonable under current law; however, our counsel has advised us that it is unable to
conclude affirmatively that this treatment is more likely than not to be upheld, and that alternative treatments are possible.
Moreover, our counsel’s opinion is based on market conditions as of the date of this preliminary pricing supplement and is
subject to confirmation on the pricing date.
You should consult your tax adviser regarding
all aspects of the U.S. federal tax consequences of an investment in the securities (including possible alternative treatments
of the securities). Unless otherwise stated, the following discussion is based on the treatment of each security as described in
the previous paragraph.
Tax Consequences to U.S. Holders
This section applies to you only if you are
a U.S. Holder. As used herein, the term “U.S. Holder” means a beneficial owner of a security that is, for U.S. federal
income tax purposes:
· a
citizen or individual resident of the United States;
· a
corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state
thereof or the District of Columbia; or
· an
estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
Tax Treatment of the Securities
Assuming the treatment of the securities as
set forth above is respected, the following U.S. federal income tax consequences should result.
Tax Basis. A U.S. Holder’s tax
basis in the securities should equal the amount paid by the U.S. Holder to acquire the securities.
Tax Treatment of Coupon Payments.
Any coupon payment on the securities should be taxable as ordinary income to a U.S. Holder at the time received or accrued, in
accordance with the U.S. Holder’s regular method of accounting for U.S. federal income tax purposes.
Sale, Exchange or Settlement of the
Securities. Upon a sale, exchange or settlement of the securities, a U.S. Holder should recognize gain or loss equal to the
difference between the amount realized on the sale, exchange or settlement and the U.S. Holder’s tax basis in the securities
sold, exchanged or settled. For this purpose, the amount realized does not include any coupon paid at settlement and may not include
sale proceeds attributable to an accrued coupon, which may be treated as a coupon payment. Any such gain or loss recognized should
be long-term capital gain or loss if the U.S. Holder has held the securities for more than one year at the time of the sale, exchange
or settlement, and should be short-term capital gain or loss otherwise. The ordinary income treatment of the coupon payments, in
conjunction with the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could
result in adverse tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations.
Possible Alternative Tax Treatments of
an Investment in the Securities
Due to the absence of authorities that directly
address the proper tax treatment of the securities, no assurance can be given that the IRS will accept, or that a court will uphold,
the treatment described above. In particular, the IRS could seek to analyze the U.S. federal income tax consequences of owning
the securities under Treasury regulations governing contingent payment debt instruments (the “Contingent Debt Regulations”).
If the IRS were successful in asserting that the Contingent Debt Regulations applied to the securities, the timing and character
of income thereon would be significantly affected. Among other things, a
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
U.S. Holder would be required to accrue into
income original issue discount on the securities every year at a “comparable yield” determined at the time of their
issuance, adjusted upward or downward to reflect the difference, if any, between the actual and the projected amount of any contingent
payments on the securities. Furthermore, any gain realized by a U.S. Holder at maturity or upon a sale, exchange or other disposition
of the securities would be treated as ordinary income, and any loss realized would be treated as ordinary loss to the extent of
the U.S. Holder’s prior accruals of original issue discount and as capital loss thereafter. The risk that financial instruments
providing for buffers, triggers or similar downside protection features, such as the securities, would be recharacterized as debt
is greater than the risk of recharacterization for comparable financial instruments that do not have such features.
Other alternative federal income tax treatments
of the securities are possible, which, if applied, could significantly affect the timing and character of the income or loss with
respect to the securities. In 2007, the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S.
federal income tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses on whether
to require holders of “prepaid forward contracts” and similar instruments to accrue income over the term of their investment.
It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments;
whether short-term instruments should be subject to any such accrual regime; the relevance of factors such as the exchange–traded
status of the instruments and the nature of the underlying property to which the instruments are linked; whether these instruments
are or should be subject to the “constructive ownership” rule, which very generally can operate to recharacterize certain
long-term capital gain as ordinary income and impose an interest charge; and appropriate transition rules and effective dates.
While it is not clear whether instruments such as the securities would be viewed as similar to the prepaid forward contracts described
in the notice, any Treasury regulations or other guidance promulgated after consideration of these issues could materially and
adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect. U.S. Holders should
consult their tax advisers regarding the U.S. federal income tax consequences of an investment in the securities, including possible
alternative treatments and the issues presented by this notice.
Backup Withholding and Information Reporting
Backup withholding may apply in respect of
payments on the securities and the payment of proceeds from a sale, exchange or other disposition of the securities, unless a U.S.
Holder provides proof of an applicable exemption or a correct taxpayer identification number and otherwise complies with applicable
requirements of the backup withholding rules. The amounts withheld under the backup withholding rules are not an additional tax
and may be refunded, or credited against the U.S. Holder’s U.S. federal income tax liability, provided that the required
information is timely furnished to the IRS. In addition, information returns will be filed with the IRS in connection with
payments on the securities and the payment of proceeds from a sale, exchange or other disposition of the securities, unless the
U.S. Holder provides proof of an applicable exemption from the information reporting rules.
Tax Consequences to Non-U.S. Holders
This section applies to you only if you are
a Non-U.S. Holder. As used herein, the term “Non-U.S. Holder” means a beneficial owner of a security that is for U.S.
federal income tax purposes:
· an
individual who is classified as a nonresident alien;
· a
foreign corporation; or
· a
foreign estate or trust.
The term “Non-U.S. Holder” does
not include any of the following holders:
· a
holder who is an individual present in the United States for 183 days or more in the taxable year of disposition and who is not
otherwise a resident of the United States for U.S. federal income tax purposes;
· certain
former citizens or residents of the United States; or
· a
holder for whom income or gain in respect of the securities is effectively
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
connected with the conduct of
a trade or business in the United States.
Such holders should consult their tax advisers
regarding the U.S. federal income tax consequences of an investment in the securities.
Although significant aspects of the tax treatment
of each security are uncertain, we intend to withhold on any coupon paid to a Non-U.S. Holder generally at a rate of 30% or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision. We will not
be required to pay any additional amounts with respect to amounts withheld. In order to claim an exemption from, or a reduction
in, the 30% withholding tax, a Non-U.S. Holder of the securities must comply with certification requirements to establish that
it is not a U.S. person and is eligible for such an exemption or reduction under an applicable tax treaty. If you are a Non-U.S.
Holder, you should consult your tax adviser regarding the tax treatment of the securities, including the possibility of obtaining
a refund of any withholding tax and the certification requirement described above.
Section 871(m) Withholding Tax on Dividend
Equivalents
Section 871(m) of the Code and Treasury regulations
promulgated thereunder (“Section 871(m)”) generally impose a 30% (or a lower applicable treaty rate) withholding tax
on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities
or indices that include U.S. equities (each, an “Underlying Security”). Subject to certain exceptions, Section 871(m)
generally applies to securities that substantially replicate the economic performance of one or more Underlying Securities, as
determined based on tests set forth in the applicable Treasury regulations (a “Specified Security”). However, pursuant
to an IRS notice, Section 871(m) will not apply to securities issued before January 1, 2021 that do not have a delta of one with
respect to any Underlying Security. Based on the terms of the securities and current market conditions, we expect that the securities
will not have a delta of one with respect to any Underlying Security on the pricing date. However, we will provide an updated determination
in the pricing supplement. Assuming that the securities do not have a delta of one with respect to any Underlying Security, our
counsel is of the opinion that the securities should not be Specified Securities and, therefore, should not be subject to Section
871(m).
Our determination is not binding on the IRS,
and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances,
including whether you enter into other transactions with respect to an Underlying Security. If Section 871(m) withholding is required,
we will not be required to pay any additional amounts with respect to the amounts so withheld. You should consult your tax adviser
regarding the potential application of Section 871(m) to the securities.
U.S. Federal Estate Tax
Individual Non-U.S. Holders and entities the
property of which is potentially includible in such an individual’s gross estate for U.S. federal estate tax purposes (for
example, a trust funded by such an individual and with respect to which the individual has retained certain interests or powers)
should note that, absent an applicable treaty exemption, the securities may be treated as U.S.-situs property subject to U.S. federal
estate tax. Prospective investors that are non-U.S. individuals, or are entities of the type described above, should consult their
tax advisers regarding the U.S. federal estate tax consequences of an investment in the securities.
Backup Withholding and Information Reporting
Information returns will be filed with the
IRS in connection with any coupon payment and may be filed with the IRS in connection with the payment at maturity on the securities
and the payment of proceeds from a sale, exchange or other disposition. A Non-U.S. Holder may be subject to backup withholding
in respect of amounts paid to the Non-U.S. Holder, unless such Non-U.S. Holder complies with certification procedures to establish
that it is not a U.S. person for U.S. federal income tax purposes or otherwise establishes an exemption. The amount of any backup
withholding from a payment to a Non-U.S. Holder will be allowed as a credit against the Non-U.S. Holder’s U.S. federal income
tax liability and may entitle the Non-U.S. Holder to a refund, provided that the required information is timely furnished to the
IRS.
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
FATCA
Legislation commonly referred to as “FATCA”
generally imposes a withholding tax of 30% on payments to certain non-U.S. entities (including financial intermediaries) with respect
to certain financial instruments, unless various U.S. information reporting and due diligence requirements have been satisfied.
An intergovernmental agreement between the United States and the non-U.S. entity’s jurisdiction may modify these requirements.
FATCA generally applies to certain financial instruments that are treated as paying U.S.-source interest or other U.S.-source “fixed
or determinable annual or periodical” income (“FDAP income”). Withholding (if applicable) applies to payments
of U.S.-source FDAP income and to payments of gross proceeds of the disposition (including upon retirement) of certain financial
instruments treated as providing for U.S.-source interest or dividends. Under recently proposed regulations (the preamble to which
specifies that taxpayers are permitted to rely on them pending finalization), no withholding will apply on payments of gross proceeds
(other than amounts treated as FDAP income). While the treatment of the securities is unclear, you should assume that any coupon
payment with respect to the securities will be subject to the FATCA rules. If withholding applies to the securities, we will not
be required to pay any additional amounts with respect to amounts withheld. Both U.S. and Non-U.S. Holders should consult their
tax advisers regarding the potential application of FATCA to the securities.
The discussion in the preceding paragraphs, insofar as it
purports to describe provisions of U.S. federal income tax laws or legal conclusions with respect thereto, constitutes the full
opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of an investment in the securities.
|
Use of proceeds and hedging:
|
The proceeds from the sale of the securities will be used by
us for general corporate purposes. We will receive, in aggregate, $1,000 per security issued, because, when we enter into hedging
transactions in order to meet our obligations under the securities, our hedging counterparty will reimburse the cost of the agent’s
commissions. The costs of the securities borne by you and described beginning on page 6 above comprise the agent’s commissions
and the cost of issuing, structuring and hedging the securities.
On or prior to the pricing date, we expect to hedge our anticipated
exposure in connection with the securities by entering into hedging transactions with our affiliates and/or third-party dealers.
We expect our hedging counterparties to take positions in the underlying stocks, in futures and/or options contracts on the underlying
stocks, or positions in any other available securities or instruments that they may wish to use in connection with such hedging.
Such purchase activity could potentially increase the initial share price of an underlying stock, and, therefore, could potentially
increase (i) the value at or above which such underlying stock must close on the redemption determination dates so that the securities
are redeemed prior to maturity for the early redemption payment (depending also on the performance of the other underlying stocks),
(ii) the coupon threshold level for such underlying stock, which is the value at or above which the underlying stock must close
on the observation dates so that you receive a contingent monthly coupon on the securities (depending also on the performance of
the other underlying stocks), and (iii) the downside threshold level for such underlying stock, which is the value at or above
which such underlying stock must close on the final observation date so that you are not exposed to the negative performance of
the underlying stock at maturity (depending also on the performance of the other underlying stocks). These entities may be unwinding
or adjusting hedge positions during the term of the securities, and the hedging strategy may involve greater and more frequent
dynamic adjustments to the hedge as the final observation date approaches. Additionally, our hedging activities, as well as our
other trading activities, during the term of the securities could potentially affect the value of any underlying stock on the redemption
determination dates and other observation dates, and, accordingly, whether we redeem the securities prior to maturity, whether
we pay a contingent monthly coupon on the securities and the amount of cash you will receive at maturity, if any (depending also
on the performance of the other underlying stocks). For further information on our use of proceeds and hedging, see “Use
of Proceeds and Hedging” in the accompanying product supplement.
|
Benefit plan investor considerations:
|
Each fiduciary of a pension, profit-sharing or other employee benefit plan subject to Title I of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (a “Plan”), should consider the fiduciary standards of ERISA in the context of the Plan’s particular circumstances before authorizing an investment in the securities. Accordingly, among other factors, the fiduciary should consider whether the investment would satisfy the prudence and
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
diversification requirements of ERISA and would be consistent
with the documents and instruments governing the Plan.
In addition, we and certain of our affiliates, including MS &
Co., may each be considered a “party in interest” within the meaning of ERISA, or a “disqualified person”
within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”), with respect to many Plans, as well
as many individual retirement accounts and Keogh plans (such accounts and plans, together with other plans, accounts and arrangements
subject to Section 4975 of the Code, also “Plans”). ERISA Section 406 and Code Section 4975 generally prohibit transactions
between Plans and parties in interest or disqualified persons. Prohibited transactions within the meaning of ERISA or the Code
would likely arise, for example, if the securities are acquired by or with the assets of a Plan with respect to which MS &
Co. or any of its affiliates is a service provider or other party in interest, unless the securities are acquired pursuant to an
exemption from the “prohibited transaction” rules. A violation of these “prohibited transaction” rules
could result in an excise tax or other liabilities under ERISA and/or Section 4975 of the Code for those persons, unless exemptive
relief is available under an applicable statutory or administrative exemption.
The U.S. Department of Labor has issued five prohibited transaction
class exemptions (“PTCEs”) that may provide exemptive relief for direct or indirect prohibited transactions resulting
from the purchase or holding of the securities. Those class exemptions are PTCE 96-23 (for certain transactions determined by in-house
asset managers), PTCE 95-60 (for certain transactions involving insurance company general accounts), PTCE 91-38 (for certain transactions
involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company separate accounts)
and PTCE 84-14 (for certain transactions determined by independent qualified professional asset managers). In addition, ERISA Section
408(b)(17) and Code Section 4975(d)(20) provide an exemption for the purchase and sale of securities and the related lending transactions,
provided that neither the issuer of the securities nor any of its affiliates has or exercises any discretionary authority or control
or renders any investment advice with respect to the assets of the Plan involved in the transaction and provided further that the
Plan pays no more, and receives no less, than “adequate consideration” in connection with the transaction (the so-called
“service provider” exemption). There can be no assurance that any of these class or statutory exemptions will be available
with respect to transactions involving the securities.
Because we may be considered a party in interest with respect
to many Plans, the securities may not be purchased, held or disposed of by any Plan, any entity whose underlying assets include
“plan assets” by reason of any Plan’s investment in the entity (a “Plan Asset Entity”) or any person
investing “plan assets” of any Plan, unless such purchase, holding or disposition is eligible for exemptive relief,
including relief available under PTCEs 96-23, 95-60, 91-38, 90-1, 84-14 or the service provider exemption or such purchase, holding
or disposition is otherwise not prohibited. Any purchaser, including any fiduciary purchasing on behalf of a Plan, transferee or
holder of the securities will be deemed to have represented, in its corporate and its fiduciary capacity, by its purchase and holding
of the securities that either (a) it is not a Plan or a Plan Asset Entity and is not purchasing such securities on behalf of or
with “plan assets” of any Plan or with any assets of a governmental, non-U.S. or church plan that is subject to any
federal, state, local or non-U.S. law that is substantially similar to the provisions of Section 406 of ERISA or Section 4975 of
the Code (“Similar Law”) or (b) its purchase, holding and disposition of these securities will not constitute or result
in a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Code or violate any Similar Law.
Due to the complexity of these rules and the penalties that may
be imposed upon persons involved in non-exempt prohibited transactions, it is particularly important that fiduciaries or other
persons considering purchasing the securities on behalf of or with “plan assets” of any Plan consult with their counsel
regarding the availability of exemptive relief.
The securities are contractual financial instruments. The financial
exposure provided by the securities is not a substitute or proxy for, and is not intended as a substitute or proxy for, individualized
investment management or advice for the benefit of any purchaser or holder of the securities. The securities have not been designed
and will not be administered in a manner intended to reflect the individualized needs and objectives of any purchaser or holder
of the securities.
Each purchaser or holder of any securities acknowledges and agrees
that:
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
(i) the
purchaser or holder or its fiduciary has made and shall make all investment decisions for the purchaser or holder and the purchaser
or holder has not relied and shall not rely in any way upon us or our affiliates to act as a fiduciary or adviser of the purchaser
or holder with respect to (A) the design and terms of the securities, (B) the purchaser or holder’s investment in the securities,
or (C) the exercise of or failure to exercise any rights we have under or with respect to the securities;
(ii) we
and our affiliates have acted and will act solely for our own account in connection with (A) all transactions relating to the
securities and (B) all hedging transactions in connection with our obligations under the securities;
(iii) any
and all assets and positions relating to hedging transactions by us or our affiliates are assets and positions of those entities
and are not assets and positions held for the benefit of the purchaser or holder;
(iv) our
interests are adverse to the interests of the purchaser or holder; and
(v) neither
we nor any of our affiliates is a fiduciary or adviser of the purchaser or holder in connection with any such assets, positions
or transactions, and any information that we or any of our affiliates may provide is not intended to be impartial investment advice.
Each purchaser and holder of the securities has exclusive responsibility
for ensuring that its purchase, holding and disposition of the securities do not violate the prohibited transaction rules of ERISA
or the Code or any Similar Law. The sale of any securities to any Plan or plan subject to Similar Law is in no respect a representation
by us or any of our affiliates or representatives that such an investment meets all relevant legal requirements with respect to
investments by plans generally or any particular plan, or that such an investment is appropriate for plans generally or any particular
plan. In this regard, neither this discussion nor anything provided in this document is or is intended to be investment advice
directed at any potential Plan purchaser or at Plan purchasers generally and such purchasers of these securities should consult
and rely on their own counsel and advisers as to whether an investment in these securities is suitable.
However, individual retirement accounts, individual retirement
annuities and Keogh plans, as well as employee benefit plans that permit participants to direct the investment of their accounts,
will not be permitted to purchase or hold the securities if the account, plan or annuity is for the benefit of an employee of Morgan
Stanley or Morgan Stanley Wealth Management or a family member and the employee receives any compensation (such as, for example,
an addition to bonus) based on the purchase of the securities by the account, plan or annuity.
|
Additional considerations:
|
Client accounts over which Morgan Stanley, Morgan Stanley Wealth Management or any of their respective subsidiaries have investment discretion are not permitted to purchase the securities, either directly or indirectly.
|
Supplemental information regarding plan of distribution; conflicts of interest:
|
Selected dealers, which may include our affiliates, and their
financial advisors will collectively receive from the agent a fixed sales commission of $ for each security they sell.
MS & Co. is an affiliate of MSFL and a wholly owned subsidiary
of Morgan Stanley, and it and other affiliates of ours expect to make a profit by selling, structuring and, when applicable, hedging
the securities. When MS & Co. prices this offering of securities, it will determine the economic terms of the securities, including
the contingent monthly coupon rate, such that for each security the estimated value on the pricing date will be no lower than the
minimum level described in “Investment Summary” beginning on page 4.
MS & Co. will conduct this offering in compliance with the
requirements of FINRA Rule 5121 of the Financial Industry Regulatory Authority, Inc., which is commonly referred to as FINRA, regarding
a FINRA member firm’s distribution of the securities of an affiliate and related conflicts of interest. MS & Co. or any
of our other affiliates may not make sales in this offering to any discretionary account. See “Plan of Distribution (Conflicts
of Interest)” and “Use of Proceeds and Hedging” in the accompanying product supplement for auto-callable securities.
|
Where you can find more information:
|
MSFL and Morgan Stanley have filed a registration statement (including
a prospectus, as supplemented by the product supplement for auto-callable securities) with the Securities and Exchange Commission,
or SEC, for the offering to which this communication relates. You should read the prospectus in that registration statement, the
product supplement for auto-callable securities and any other documents relating to this offering that MSFL and Morgan
|
Morgan Stanley Finance LLC
Contingent Income Auto-Callable Securities due November 26, 2024, with 3-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the Common Stock of Sarepta Therapeutics, Inc., the Common Stock of Western Digital Corporation and the Common Stock of Kohl’s Corporation
Principal at Risk Securities
|
Stanley have filed with the SEC for more complete information
about MSFL, Morgan Stanley and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at.www.sec.gov.
Alternatively, MSFL, Morgan Stanley, any underwriter or any dealer participating in the offering will arrange to send you the prospectus
and the product supplement for auto-callable securities if you so request by calling toll-free 1-(800)-584-6837.
You may access these documents on the SEC web site at.www.sec.gov
as follows:
Product
Supplement for Auto-Callable Securities dated November 16, 2017
Prospectus
dated November 16, 2017
Terms used but not defined in this document are defined in the
product supplement for auto-callable securities or in the prospectus.
|
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024